TwoOncDocs

Looking forward to a great weekend at #ASCO26. Two chances to hear about our survey of AI in HOF on 5/31 at 9:45 and 16:55 🗣️ See everyone here in Chicago soon!!

In the era of @EvidenceOpen, @UpToDate, and podcasts (shoutout to @TwoOncDocs and @OncBrothers), all tools I use daily, there’s still something nice about having a practical resource you can carry in clinic or on rounds, especially as an early trainee. 🩺 Plus, the timeless feeling of holding a book 📗 Proud to have contributed as an associate editor for the 4th edition of Pocket Oncology and to help continue this @MSKCancerCenter tradition. Congrats to @JessieStuart316 and @jimmitti_teysir for the amazing work that went into this edition, alongside @AlexDrilon and @yoninamg. ➡️🔗Available here: shorturl.at/3K4SZ #oncology #MedTwitter #MedEd

W/ #ASCO26 around the corner, tune in for our preview on GU, #MedEd & more: 📖 board review w/ @OncBrothers 5/29! bit.ly/boards2026 🌟 survey of AI in HOF: 5/31 Not to miss ed sessions: 💊 KRAS- drugs @ASCOPres & @lillian_siu: 5/30 1:15-2:30 🧬 Personalization 🌎 Access

Answer is C) 🔑 Type 2B VWD is a gain-of-function defect → VWF has INCREASED affinity for platelet GPIb 🔑 This causes spontaneous VWF-platelet binding in circulation → consumption of both platelets AND large multimers Memory tip: 2B = "Bites up platelets" 🦷

Last week we did an update on Aplastic Anemia, and this week we are back with an update on the highly testable Von Willebrand disease 🩸🩸🩸 Which of the following VWD subtypes is characteristically associated w/ thrombocytopenia? @HemOncFellows

Fellows, every chance you get watch your attendings do goals of care conversations with patients and families. Some will really suck at it while others will excel and truly be inspirational. You will learn what works and what doesn't.

@RupClevelandCli @Papa_Heme @OncBrothers Also high-yield podcasts for commutes: @OncBrothers @TwoOncDocs @DrNeilLove

@RupClevelandCli @Papa_Heme 1. See as many patients as possible. 2. Ask a lot of questions 3. There are a lot of resources… (LLMs, Podcasts, books, articles). Pick a few that work best for you. For podcasts: @TwoOncDocs & @TheFellowOnCall 4. See as many patients as possible!!

Great discussion on Pancreatic Cancer and its supportive care. So thankful for @twooncdocs for these podcasts. @MPishvaian podcasts.apple.com/us/podcast/two…

Answer is B) preferred TMT regimens include: Cisplatin + 5-Fluorouracil (5-FU) Mitomycin-C + 5-Fluorouracil (5-FU) Cisplatin alone Low-dose Gemcitabine

We are back this week with 2026 updates on Localized Bladder Cancer 🧡 A 67M with a 4cm urothelial carcinoma invading the muscularis propria, presents to discuss tx options, he does NOT want a cystectomy. CrCl is 60. What treatment options do you offer? @HemOncFellows

The answer is D) ALL patients with pancreatic cancer should undergo germline testing!

4 years w/ @TwoOncDocs ! 🎉 We celebrated w/ a special episode on how we met, why this podcast & why oncology Last week we completed a 3 part series on #PancreaticCancer w/ the expert @MPishvaian Which of these scenarios should get germline testing? @PanCAN @PanCanResearch

🤔 Going to @ASCO 26, join for a FREE board review! 🗓️In-person Oncology Board Review w/@TwoOncDocs +@OncBrothers 🔗Link to register: bit.ly/boards2026 👉Share with your fellows or tag someone studying for boards #OncTwitter #MedEd #FOAMed #Oncology #MedTwitter #MedX

A MUST-READ! This is probably one of my most important papers where I try to teach how to fish rather than offer fish. How I Read a Clinical Trial Report? BG’s primer for Busy Clinicians. Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful. ascopubs.org/doi/10.1200/OP…

🤔Headed to #ASCO26 📍Mark these can’t miss events on your 🗓️ calendar! 🔥Oncology Board Review w/ @TwoOncDocs on May 28th! @OncBrothers will be LIVE @ASCO on May 30th! 👉Share with your fellows or anyone needing a review for boards! @ASCOTECAG @HemOncFellows #OncTwitter

🌟3🌟 part Pancreatic Cancer updates with our very special guest @MPishvaian from @TumorBoardTues 💜 Part 1: risk factors, germline & somatic testing, diagnosis & localized tx - out this week! Part 2: tx paradigm for metastatic pancreatic CA Part 3: supportive care & trials

Great discussion last night #TumorBoardTuesday @PGrivasMDPhD, tune in for full thread on: 💥Tx for MIBC cis (in)eligible & key trial data ✨TMT criteria & regimens 💫CtDNA data in MIBC 🌟AEs of EVP ⚡️variant histology & we will update @TwoOncDocs UC episodes next month!

#PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 integrityce.com/TBT2025 🤔Which of the following is a preferred approach for patients with muscle-invasive bladder cancer with low renal function❓ @PGrivasMDPhD @TumorBoardTues @OncBrothers @TwoOncDocs @tompowles1 @AmandaNizamMD

#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 integrityce.com/TBTeval25 👉🏽ALL CME🔗 integrityce.com/TBT2025 🤔Which is a preferred PeriOp Tx for a fit cisplatin-eligible patient with muscle-invasive bladder cancer❓ @PGrivasMDPhD @TumorBoardTues @OncBrothers @TwoOncDocs